OpenEvidence

OpenEvidence is a medical AI company building what it describes as the leading AI-powered medical information platform, with a mission to organize the world's medical knowledge and make it more open, accessible, and understandable. It was founded by Daniel Nadler (PhD, Harvard; previously founder of Kensho Technologies) and launched out of the Mayo Clinic Platform Accelerate program, and has been featured by the New England Journal of Medicine AI. The company has assembled a team of AI researchers from Harvard, MIT, and Stanford alongside a roster of medical advisors from institutions including Mayo Clinic, Cedars-Sinai, UCSF, Cleveland Clinic, and Massachusetts General Hospital.

The product is reported to be one of the fastest-growing applications for physicians, trusted by medical professionals at more than 10,000 care centers across the United States. It operates a distinctive business model: the service is free for verified U.S. clinicians and monetized through advertising, and it maintains content partnerships with major publishers such as the New England Journal of Medicine and the JAMA Network.

The core product lets a verified clinician ask a natural-language clinical question and receive a synthesized answer that aggregates and summarizes relevant evidence, with inline citations linking back to the primary studies, reviews, and guidelines. It draws on the broad medical literature plus partner content from NEJM and JAMA Network, aiming to help physicians keep up with a body of research that is doubling roughly every five years. Answers are conversational and support follow-up questions.

OpenEvidence is available on the web and through native iOS and Android apps, gated behind HCP verification. The company is explicit that the tool is a technology demonstrator that does not provide medical advice, diagnosis, or treatment, that inputs are not covered by HIPAA, and that users must avoid submitting protected health information.

OpenEvidence targets licensed healthcare professionals in the United States: physicians and specialists, nurse practitioners, physician assistants, pharmacists, and medical residents and trainees. Access is limited to users who complete HCP verification, so the platform is deliberately not aimed at patients or general consumers. Its value proposition centers on fast, evidence-based answers at the point of care and staying current with the rapidly expanding medical literature.

OpenEvidence has raised roughly $700 million across a rapid sequence of rounds. Reported milestones include a ~$75M Series A led by Sequoia Capital in early 2025 at a ~$1B valuation; a $210M Series B co-led by GV and Kleiner Perkins in July 2025 at a $3.5B valuation; a ~$200M Series C led by GV in October 2025 at a ~$6B valuation; and a $250M Series D led by Thrive Capital and DST Global reported in early 2026 at a ~$12B valuation. Investors include Sequoia Capital, GV (Google Ventures), Kleiner Perkins, Breyer Capital, Conviction (Conviction Partners), Mayo Clinic, Blackstone, Thrive Capital, Coatue, and others.